JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Computerized Intervention for Loneliness

  NCT03839966

  Condition:   Loneliness
  Interventions:   Behavioral: Interpretation Bias Modification for Loneliness;   Behavioral: Healthy Habits Psychoeducation and Relaxation
  Sponsor:   Florida State University
  Recruiting
• Building Closer Friendships in Social Anxiety Disorder

  NCT03671577

  Condition:   Social Anxiety
  Intervention:   Behavioral: Building Closer Friendships
  Sponsor:   Florida State University
  Recruiting
• The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD

  NCT04089943

  Conditions:   Peripheral Arterial Disease;   Vascular Diseases, Peripheral;   Arterial Occlusive Diseases;   Atherosclerosis
  Interventions:   Procedure: Revascularization operation;   Other: Control group
  Sponsors:   Florida State University;   National Institute on Aging (NIA)
  Recruiting
• Iron Absorption and Exercise

  NCT04079322

  Conditions:   Iron-deficiency;   Iron Deficiency Anemia
  Intervention:   Other: Meal
  Sponsor:   Florida State University
  Recruiting
• Family Genetics Health Education and Healthy Behaviors

  NCT01498276

  Conditions:   Diabetes;   Cancer;   Heart Disease
  Intervention:  
  Sponsor:   National Human Genome Research Institute (NHGRI)
  Recruiting
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

  NCT03382899

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Biological: Pegilodecakin;   Drug: Pembrolizumab
  Sponsors:   Eli Lilly and Company;   ARMO BioSciences
  Recruiting
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

  NCT03859973

  Condition:   Schizophrenia
  Interventions:   Drug: BI 425809;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

  NCT02907177

  Condition:   Multiple Sclerosis
  Interventions:   Drug: Ponesimod;   Other: Placebo
  Sponsor:   Actelion
  Recruiting
• Post-Approval 'Real Conditions of Use' Study

  NCT02555280

  Condition:   Spinal Stenosis
  Interventions:   Device: coflex® Interlaminar Technology;   Procedure: Decompression
  Sponsors:   Paradigm Spine;   Musculoskeletal Clinical Regulatory Advisers
  Recruiting
• Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

  NCT03977467

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Atezolizumab;   Other: Chemotherapy (Arm A Only)
  Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
  Recruiting
• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer

  NCT03915951

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Drug: encorafenib;   Drug: binimetinib
  Sponsor:   Array BioPharma
  Recruiting
• Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

  NCT03781063

  Condition:   Locally Advanced or Metastatic Breast Cancer
  Interventions:   Drug: Lasofoxifene;   Drug: Fulvestrant
  Sponsors:   Sermonix Pharmaceuticals LLC;   Linical Accelovance Group
  Recruiting
• Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.

  NCT03697304

  Condition:   Neoplasm Metastasis
  Interventions:   Drug: BI 754091;   Drug: BI 754111;   Drug: BI 891065
  Sponsor:   Boehringer Ingelheim
  Recruiting
• A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

  NCT03869684

  Condition:   Age-related Macular Degeneration
  Interventions:   Drug: MT-0814;   Drug: Placebo
  Sponsors:   Senju Pharmaceutical Co., Ltd.;   PPD
  Recruiting
• This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab

  NCT04108156

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab;   Drug: Intravitreal Ranibizumab 0.5 mg Injection
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

  NCT04031885

  Condition:   Metastatic Breast Cancer
  Interventions:   Drug: Abemaciclib;   Drug: Fulvestrant;   Drug: Standard Chemotherapy
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

  NCT03972709

  Conditions:   Macular Degeneration, Age-Related;   Geographic Atrophy
  Interventions:   Drug: RO7171009;   Drug: Sham Control
  Sponsor:   Genentech, Inc.
  Recruiting
• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC

  NCT03906071

  Condition:   Non-Squamous Non-Small Cell Lung Cancer
  Interventions:   Biological: Nivolumab;   Drug: Sitravatinib;   Drug: Docetaxel
  Sponsors:   Mirati Therapeutics Inc.;   Bristol-Myers Squibb
  Recruiting
• TRILUMINATE Pivotal Trial

  NCT03904147

  Condition:   Tricuspid Regurgitation
  Intervention:   Device: Tricuspid valve repair
  Sponsor:   Abbott Medical Devices
  Recruiting
• Florida Pancreas Collaborative Next Generation Biobank

  NCT03851133

  Conditions:   Pancreatic Cancer;   Cancer Cachexia
  Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
  Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• A Study Assessing AR-13503 Implant Alone and in Combination With Aflibercept in Subjects With nAMD or DME

  NCT03835884

  Conditions:   Neovascular Age-related Macular Degeneration;   Diabetic Macular Edema
  Interventions:   Drug: AR-13503 Implant Low Dose;   Drug: AR-13503 Implant High Dose;   Drug: Aflibercept;   Other: Sham
  Sponsor:   Aerie Pharmaceuticals
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

  NCT03823300

  Condition:   Wet Macular Degeneration
  Interventions:   Drug: Faricimab;   Drug: Aflibercept;   Drug: Sham Procedure
  Sponsor:   Hoffmann-La Roche
  Recruiting
• XIENCE 28 USA Study

  NCT03815175

  Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
  Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
  Sponsor:   Abbott Medical Devices
  Recruiting
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

  NCT03701334

  Condition:   Early Breast Cancer
  Interventions:   Drug: Ribociclib;   Other: Endocrine Therapy
  Sponsors:   Novartis Pharmaceuticals;   Translational Research in Oncology
  Recruiting
• The INSPIRE-ASP UTI Trial

  NCT03697096

  Condition:   Urinary Tract Infection (UTI)
  Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
  Recruiting
• The INSPIRE-ASP PNA Trial

  NCT03697070

  Condition:   Pneumonia
  Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
  Recruiting
• GB001 in Adult Subjects With Moderate to Severe Asthma

  NCT03683576

  Condition:   Asthma
  Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
  Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
  Recruiting
• Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions

  NCT03682536

  Condition:   Myelodysplastic Syndromes
  Interventions:   Drug: Luspatercept;   Drug: Epoetin alfa
  Sponsors:   Celgene;   Acceleron Pharma, Inc.
  Recruiting
• A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

  NCT03677934

  Condition:   Neovascular Age-Related Macular Degeneration
  Interventions:   Drug: PDS Implant filled with 100 mg/mL Ranibizumab;   Drug: Intravitreal Injections of 10 mg/mL Ranibizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114

  Condition:   Relapsing Multiple Sclerosis
  Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

  NCT03635424

  Condition:   Bicuspid Aortic Valve
  Intervention:   Device: Medtronic TAVR Systems
  Sponsor:   Medtronic Cardiovascular
  Recruiting
• Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

  NCT03521934

  Condition:   Heart Failure-Type 2 Diabetes Mellitus
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

  NCT03447769

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Canakinumab;   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

  NCT03433274

  Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Insufficiency;   Cardiovascular Diseases;   Valve Disease, Heart;   Heart Valve Diseases;   Functional Mitral Regurgitation;   Degenerative Mitral Valve Disease
  Interventions:   Device: Tendyne Mitral Valve System;   Device: MitraClip System
  Sponsor:   Tendyne Holdings, Inc.
  Recruiting
• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045

  Condition:   Asthma
  Intervention:  
  Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
  Recruiting
• Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

  NCT03372161

  Condition:   Lumbosacral Radicular Pain
  Interventions:   Drug: SP-102;   Drug: Placebo
  Sponsors:   Semnur Pharmaceuticals, Inc.;   Worldwide Clinical Trials
  Recruiting
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

  NCT03326674

  Condition:   Breast Cancer
  Interventions:   Drug: Tesetaxel and Capecitabine;   Drug: Capecitabine
  Sponsor:   Odonate Therapeutics, Inc.
  Recruiting
• Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

  NCT03283371

  Condition:   Epilepsy, Focal Seizures, Partial Seizures
  Interventions:   Drug: Natalizumab;   Other: Placebo
  Sponsor:   Biogen
  Recruiting
• Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)

  NCT03257436

  Condition:   Left Ventricular Dysfunction
  Intervention:   Device: CRT-D
  Sponsors:   Boston Scientific Corporation;   ICON Clinical Research
  Recruiting
• Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771

  Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
  Interventions:   Device: Orbital Atherectomy;   Device: Balloon
  Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
  Recruiting
• RESOLUTE ONYX Post-Approval Study

  NCT03063749

  Condition:   Coronary Artery Disease
  Intervention:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
  Sponsor:   Medtronic Vascular
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347

  Condition:   Treatment Naive Follicular Lymphoma
  Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
  Sponsor:   Pharmacyclics LLC.
  Recruiting
• Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

  NCT02943785

  Condition:   Atrial Fibrillation
  Interventions:   Drug: Edoxaban-based Regimen;   Drug: VKA-based Regimen
  Sponsors:   Daiichi Sankyo, Inc.;   Chiltern International Inc.
  Recruiting
• Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

  NCT02923726

  Condition:   Sudden Cardiac Death
  Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
  Sponsors:   Boston Scientific Corporation;   ICON plc
  Recruiting
• Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

  NCT02923193

  Condition:   Peripheral Arterial Disease
  Interventions:   Device: Shockwave Lithoplasty® Peripheral Lithoplasty System;   Drug: Medtronic IN.PACT (DCB)
  Sponsor:   Shockwave Medical, Inc.
  Recruiting
• Memory Gel and Shape Combined Cohort

  NCT02919592

  Conditions:   Primary Breast Augmentation;   Primary Breast Reconstruction;   Revision Breast Augmentation;   Revision Breast Reconstruction
  Interventions:   Device: MemoryShape® Breast Implants;   Device: MemoryGel® Breast Implants;   Procedure: Other Aesthetic Surgery
  Sponsor:   Mentor Worldwide, LLC
  Recruiting
• Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

  NCT02793583

  Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• SPYRAL HTN-ON MED Study

  NCT02439775

  Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
  Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
  Sponsor:   Medtronic Vascular
  Recruiting
• SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

  NCT02439749

  Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
  Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
  Sponsor:   Medtronic Vascular
  Recruiting
• Web Based Orthopaedic Sports Medicine Registry

  NCT01191151

  Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
  Intervention:  
  Sponsor:   Arthrex, Inc.
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

  NCT03580369

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting